MX378439B - Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina. - Google Patents

Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina.

Info

Publication number
MX378439B
MX378439B MX2015008993A MX2015008993A MX378439B MX 378439 B MX378439 B MX 378439B MX 2015008993 A MX2015008993 A MX 2015008993A MX 2015008993 A MX2015008993 A MX 2015008993A MX 378439 B MX378439 B MX 378439B
Authority
MX
Mexico
Prior art keywords
formula
triazine
radio
compound
imaging agents
Prior art date
Application number
MX2015008993A
Other languages
English (en)
Other versions
MX2015008993A (es
Inventor
John W Babich
John Joyal
Genliang Lu
Craig Zimmerman
Original Assignee
Molecular Insight Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Insight Pharm Inc filed Critical Molecular Insight Pharm Inc
Publication of MX2015008993A publication Critical patent/MX2015008993A/es
Publication of MX378439B publication Critical patent/MX378439B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos de conformidad con la Fórmula (I) y la Fórmula (II) son potentes inhibidores de PSMA; las composiciones farmacéuticas (I) o (II) pueden incluir un complejo de un radionucleido y un compuesto de Fórmula (I) o un compuesto de Fórmula (II) los métodos incluyen usar el complejo de radionucleido de un compuesto de Fórmula (I) o un compuesto de Fórmula (II) para tratar o diagnosticar una enfermedad o afección asociada con actividad de PSMA.
MX2015008993A 2013-01-14 2014-01-10 Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina. MX378439B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752350P 2013-01-14 2013-01-14
US201361785788P 2013-03-14 2013-03-14
PCT/US2014/011047 WO2014110372A1 (en) 2013-01-14 2014-01-10 Triazine based radiopharmaceuticals and radioimaging agents

Publications (2)

Publication Number Publication Date
MX2015008993A MX2015008993A (es) 2016-04-04
MX378439B true MX378439B (es) 2025-03-11

Family

ID=51167394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008993A MX378439B (es) 2013-01-14 2014-01-10 Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina.

Country Status (14)

Country Link
US (5) US9447121B2 (es)
EP (4) EP3300746B1 (es)
JP (2) JP6468602B2 (es)
KR (1) KR102187940B1 (es)
CN (1) CN105025933B (es)
AU (1) AU2014205304B2 (es)
BR (1) BR112015016585B1 (es)
CA (1) CA2897437C (es)
ES (2) ES2738474T3 (es)
HU (2) HUE044552T2 (es)
MX (1) MX378439B (es)
PL (2) PL3300746T3 (es)
SG (1) SG11201505477TA (es)
WO (1) WO2014110372A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897437C (en) * 2013-01-14 2021-12-14 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
GEP20237479B (en) 2013-10-18 2023-03-27 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10683272B2 (en) * 2014-05-06 2020-06-16 The Johns Hopkins University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
US9956305B2 (en) 2014-09-08 2018-05-01 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
KR20250057132A (ko) * 2016-03-22 2025-04-28 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
AU2017348111B2 (en) * 2016-10-27 2023-04-06 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
US11478558B2 (en) 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
MX388833B (es) * 2017-06-19 2025-03-12 Futurechem Co Ltd Compuesto marcado con 18f para diagnostico de cancer de prostata y uso de este
WO2018236115A1 (ko) * 2017-06-19 2018-12-27 (주)퓨쳐켐 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
DK3778592T3 (da) 2018-03-30 2023-06-19 Futurechem Co Ltd PSMA-målrettet radiolægemiddel til diagnosticering og behandling af prostatacancer
EP3883613A1 (en) 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
CA3137963A1 (en) * 2019-04-26 2020-10-29 Five Eleven Pharma Inc. Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents
AU2022396942A1 (en) * 2021-11-24 2024-05-23 Clarity Pharmaceuticals Ltd Compounds and compositions thereof for the treatment of cancer
CN116199736B (zh) * 2023-03-01 2025-03-18 西南医科大学附属医院 一种DOTA-Te-PSMA化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2730457A (en) 1953-06-30 1956-01-10 Ncr Co Pressure responsive record materials
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US2730456A (en) 1953-06-30 1956-01-10 Ncr Co Manifold record material
US3527789A (en) 1967-10-06 1970-09-08 Shell Oil Co Production of poly(lower)alkyl alkenepolycarboxylates
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
JPS5220203B2 (es) 1973-03-05 1977-06-02
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS6131056A (ja) 1984-07-25 1986-02-13 K Baiorojikaru Sci Lab:Kk ホイッピングクリームの製造方法
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
JP2608550B2 (ja) 1986-10-17 1997-05-07 株式会社 片山化学工業研究所 軟水ボイラの防食処理方法
US4888136A (en) 1988-05-02 1989-12-19 Witco Corporation New flame retardant compositions of matter and cellulosic products containing same
TW353663B (en) 1991-04-06 1999-03-01 Hoechst Ag Process for the preparation of phosphorus-containing L-amino acids, their derivatives and intermediates for this process
JP3051497B2 (ja) 1991-05-17 2000-06-12 株式会社第一ラジオアイソトープ研究所 スルファニルアミド誘導体のテクネチウム錯体をもちいる放射性診断剤
IL103353A (en) 1991-10-29 1999-01-26 Bracco Int Bv Ligand metal complexes thereof diagnostic composition and processes for their preparation
US6359120B1 (en) 1991-10-29 2002-03-19 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia-localizing moiety
IT1270260B (it) 1994-06-21 1997-04-29 Zambon Spa Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
JP2856098B2 (ja) 1995-04-11 1999-02-10 日本製紙株式会社 感熱記録シート
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6071965A (en) 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
KR20000036227A (ko) 1996-09-27 2000-06-26 토마스 씨. 서 날라다아제조성물, 글루탐산염 이상 치료법 및 동물내의 뉴우런활성법
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
EP1064273B1 (en) 1998-03-19 2002-12-18 PHARMACIA & UPJOHN COMPANY 1,3,4-thiadiazoles useful for the treatment of cmv infections
JP5095050B2 (ja) 1999-04-28 2012-12-12 ジョージタウン ユニバーシティー 代謝調節型グルタミン酸受容体のリガンド、及び、ＮＡＡＬＡＤａｓｅの阻害剤
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US6228888B1 (en) 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
WO2002094261A1 (fr) 2001-05-24 2002-11-28 Kureha Chemical Industry Company, Limited Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
JP4303595B2 (ja) 2001-12-21 2009-07-29 透 小池 アニオン性置換基を有する物質を捕捉可能な亜鉛錯体
US7408079B2 (en) 2002-01-10 2008-08-05 The Johns Hopkins University Imaging agents and methods of imaging NAALADase or PSMA
WO2003077727A2 (en) 2002-03-11 2003-09-25 Biostream, Inc. Technetium-dipyridine complexes, and methods of use thereof
EP1550657A4 (en) 2002-09-11 2009-12-30 Kureha Corp AMINO COMPOUNDS AND THEIR USE
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
AU2003295950B2 (en) 2002-11-26 2007-06-28 Institute Of Virology CA IX-specific inhibitors
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7682601B2 (en) 2003-04-15 2010-03-23 Mallinckrodt Inc. Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes
WO2005056520A1 (en) 2003-12-12 2005-06-23 Oy Juvantia Pharma Ltd Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
CA2555959A1 (en) 2004-02-12 2005-09-01 Molecular Insight Pharmaceuticals Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof
GB0421308D0 (en) 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
WO2006080993A1 (en) 2004-12-08 2006-08-03 Purdue Research Foundation Novel cationic metal complex radiopharmaceuticals
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
CA2606477C (en) 2005-04-27 2013-05-28 Siemens Medical Solutions Usa, Inc. In situ click chemistry method for screening high affinity molecular imaging probes
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
FR2890657B1 (fr) 2005-09-15 2007-11-09 Commissariat Energie Atomique Procede d'obtention de complexes de lanthanides hautement luminescents.
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
WO2007090461A1 (en) 2006-02-06 2007-08-16 Ciba Holding Inc. Use of metal complex compounds as oxidation catalysts
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
WO2007148738A1 (ja) 2006-06-20 2007-12-27 Ishihara Sangyo Kaisha, Ltd. 新規なピリジル－メタナミン誘導体又はその塩を含有する有害生物防除剤
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
BRPI0716368A2 (pt) 2006-08-29 2013-10-01 Molecular Insight Pharm Inc porÇÕes de radioimageamento acopladas a porÇÕes de ligaÇço Á peptidase para imageamento de tecidos e àrgços que expressam peptidases
EP2097111B1 (en) * 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US8610075B2 (en) 2006-11-13 2013-12-17 Biosensors International Group Ltd. Radioimaging applications of and novel formulations of teboroxime
KR20090127433A (ko) 2007-04-05 2009-12-11 지멘스 메디컬 솔루션즈 유에스에이, 인크. 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
CN102083427B (zh) 2008-01-09 2014-12-10 分子洞察制药公司 碳酸酐酶ix的抑制剂
CN102119157A (zh) * 2008-06-11 2011-07-06 阿斯利康(瑞典)有限公司 用于治疗癌症和骨髓增生性疾病的三环2，4-二氨基-l，3，5-三嗪衍生物
BRPI0919818A2 (pt) 2008-09-25 2019-09-24 Molecular Insight Pharm Inc inibidores de seprase seletivos
EP2759535A1 (en) 2008-12-05 2014-07-30 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
CA3131469A1 (en) * 2009-03-19 2010-09-23 The Johns Hopkins University Psma-targeting compounds and uses thereof
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
CA2819850C (en) 2010-12-06 2019-07-23 John W. Babich Psma-targeted dendrimers
HUE045028T2 (hu) 2011-08-05 2019-12-30 Molecular Insight Pharm Inc Radiojelzett prosztataspecifikus membrán antigén inhibitorok
US9556167B2 (en) 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
CA2897437C (en) * 2013-01-14 2021-12-14 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents

Also Published As

Publication number Publication date
EP2943227A4 (en) 2016-05-25
JP2019073532A (ja) 2019-05-16
MX2015008993A (es) 2016-04-04
EP3300746A1 (en) 2018-04-04
JP6468602B2 (ja) 2019-02-13
US10086096B2 (en) 2018-10-02
US9447121B2 (en) 2016-09-20
KR102187940B1 (ko) 2020-12-07
ES2738474T3 (es) 2020-01-23
WO2014110372A1 (en) 2014-07-17
CN105025933A (zh) 2015-11-04
AU2014205304B2 (en) 2018-03-29
BR112015016585B1 (pt) 2021-02-02
EP3939972A1 (en) 2022-01-19
US10898598B2 (en) 2021-01-26
JP6707677B2 (ja) 2020-06-10
HUE035739T2 (en) 2018-05-28
US20170296683A1 (en) 2017-10-19
EP3545978A1 (en) 2019-10-02
CA2897437A1 (en) 2014-07-17
PL3300746T3 (pl) 2019-11-29
KR20150115797A (ko) 2015-10-14
CN105025933B (zh) 2019-03-26
EP2943227B1 (en) 2017-09-20
US20140255306A1 (en) 2014-09-11
ES2648096T3 (es) 2017-12-28
CA2897437C (en) 2021-12-14
EP3545978B1 (en) 2021-09-08
US20160346410A1 (en) 2016-12-01
EP2943227A1 (en) 2015-11-18
US20210338850A1 (en) 2021-11-04
JP2016511231A (ja) 2016-04-14
AU2014205304A1 (en) 2015-08-13
HK1212908A1 (zh) 2016-06-24
PL2943227T3 (pl) 2018-02-28
US11712485B2 (en) 2023-08-01
US20190134237A1 (en) 2019-05-09
EP2943227B8 (en) 2017-11-22
BR112015016585A2 (pt) 2017-08-22
US10201624B2 (en) 2019-02-12
SG11201505477TA (en) 2015-08-28
EP3300746B1 (en) 2019-05-15
HUE044552T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
MX378439B (es) Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina.
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
DOP2014000282A (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen
TR201902709T4 (tr) Mek inhibitörleri olarak bileşikler ve bileşimler.
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY35467A (es) Compuestos orgánicos
SI3066085T1 (sl) Postopek sinteze inhibitorja indolamina 2,3-dioksigenaze
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CR20150171A (es) Benzamidas
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201591624A1 (ru) Новые производные пиразола
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
UY35333A (es) Compuestos de azabencimidazol
MX365916B (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
NI201600016A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los continen.
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CO7170173A2 (es) Derivados de carbamato/urea
AR095097A1 (es) Compuestos de fenoxietoxi
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
EA201690908A1 (ru) Пиразолопиримидиновые соединения